Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28790068 | 0.89 | HTR6 (0.52) | HTR6SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL312862 | 0.86 | SLC6A2 (0.51) | TGFBR1SLC6A2SLC6A4SLC6A3JAK2 | |
| SCHEMBL28790065 | 0.85 | SLC6A2 (0.50) | TGFBR1SLC6A2SLC6A4SLC6A3JAK2 | |
| SCHEMBL10102903 | 0.83 | HTR6 (0.52) | HTR6SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL18927009 | 0.83 | HTR6 (0.55) | HTR6TGFBR1BCHESTS | |
| SCHEMBL314139 | 0.80 | SLC6A2 (0.68) | HTR6SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL312519 | 0.80 | JAK2 (0.45) | TGFBR1SLC6A2SLC6A4SLC6A3JAK2 | |
| Trifluoroacetic Acid SCHEMBL312498 | 0.80 | SLC6A2 (0.59) | HTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27802769 | 0.79 | JAK2 (0.44) | TGFBR1SLC6A2SLC6A4SLC6A3JAK2 | |
| SCHEMBL11927335 | 0.78 | HTR6 (0.68) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2268631-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | MAOB, ADORA2B, HTR1B | HTR6 37/4885TGFBR1 3689/4885SLC6A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.